A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

Myung Sun Kim; Titas Banerjee; Andy Chen; Alexey Danilov; Renee MacKinnon; Bria Thurlow; Sujata Thakurta; Kirsten Orand; Catherine Degnin; Byung Park; Stephen E. Spurgeon

doi:10.1080/10428194.2022.2045598

A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

Myung Sun Kim, Titas Banerjee, Andy Chen, Alexey Danilov, Renee MacKinnon, Bria Thurlow, Sujata Thakurta, Kirsten Orand, Catherine Degnin, Byung Park, Stephen E. Spurgeon

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2022.2045598
State	Accepted/In press - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2022.2045598

Cite this

A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. / Kim, Myung Sun; Banerjee, Titas; Chen, Andy; Danilov, Alexey; MacKinnon, Renee; Thurlow, Bria; Thakurta, Sujata; Orand, Kirsten; Degnin, Catherine; Park, Byung ; Spurgeon, Stephen E.

In: Leukemia and Lymphoma, 2022.

Research output: Contribution to journal › Letter › peer-review

@article{d3b5659291f34bbd92d548b1625bc8e4,

title = "A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma",

author = "Kim, {Myung Sun} and Titas Banerjee and Andy Chen and Alexey Danilov and Renee MacKinnon and Bria Thurlow and Sujata Thakurta and Kirsten Orand and Catherine Degnin and Byung Park and Spurgeon, {Stephen E.}",

note = "Funding Information: A. V. D. received consulting fees from Abbvie, AstraZeneca, BeiGene, Genentech, Pharmacyclics and TG Therapeutics and has ongoing research funding from AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Genentech, MEI Pharma, SecuraBio, TG Therapeutics and Takeda Oncology.",

year = "2022",

doi = "10.1080/10428194.2022.2045598",

language = "English (US)",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

AU - Kim, Myung Sun

AU - Banerjee, Titas

AU - Chen, Andy

AU - Danilov, Alexey

AU - MacKinnon, Renee

AU - Thurlow, Bria

AU - Thakurta, Sujata

AU - Orand, Kirsten

AU - Degnin, Catherine

AU - Park, Byung

AU - Spurgeon, Stephen E.

N1 - Funding Information: A. V. D. received consulting fees from Abbvie, AstraZeneca, BeiGene, Genentech, Pharmacyclics and TG Therapeutics and has ongoing research funding from AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Genentech, MEI Pharma, SecuraBio, TG Therapeutics and Takeda Oncology.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85126361519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126361519&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2045598

DO - 10.1080/10428194.2022.2045598

M3 - Letter

C2 - 35263204

AN - SCOPUS:85126361519

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -

A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this